AMN Healthcare Services, Inc. (AMN) — ESG & Values Scores

Environment story

AMN Healthcare Services has not disclosed Scope 1, Scope 2, or Scope 3 greenhouse gas emissions, net-zero targets, renewable energy percentages, or specific decarbonization initiatives in available filings. The company operates in healthcare staffing and workforce solutions, with indirect environmental exposure primarily through business travel and data center operations (language services and SaaS platforms). No substantive environmental controversies, fines, or resource-exploitation issues identified in source documents. Lack of disclosure triggers automatic penalties under deterministic rules: -15 for undisclosed Scope 3, -15 for absent net-zero target, -0 for no detected resource controversies, +0 for unverified decarbonization infrastructure. No greenwashing detected (no offset reliance claims found).

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

AMN Healthcare Services exhibits moderate social performance with documented labor compliance risks and incomplete diversity disclosure. The company acknowledges ongoing wage-and-hour litigation exposure and NLRB investigation risks in Risk Factors, but no active major strikes or documented union-suppression activities within the past 24 months are disclosed. Leadership diversity and CEO-to-median-worker pay ratio are not disclosed in source documents; governance assumes diversity below 30% threshold and applies conservative penalty. Supply chain labor risks are acknowledged for international nurse recruitment (visa reliance) but no forced-labor or human-trafficking controversies detected. Turnover and union-standing data are absent. The company invests in workforce development and recruitment infrastructure but does not quantify DEI commitments or supplier diversity programs in available filings.

Criticisms on file

Wage-and-hour litigation exposure: Company acknowledges subject to individual, representative and class action lawsuits related to alleged wage and hour violations under California and Federal law.
Source: AMN 10-K Risk Factors: 'Investigations, claims and legal proceedings alleging medical malpractice, anti-competitive conduct, violations of employment, privacy and wage regulations'
Independent contractor classification disputes: Locum tenens physicians and advanced practitioners historically classified as independent contractors; ongoing risk of reclassification to employees in certain states.
Source: AMN 10-K Risk Factors: 'The challenge to the classification of certain of our healthcare professionals as independent contractors could adversely affect our profitability.'
International nurse visa reliance: Business model dependent on visa availability for international nurse recruitment; visa retrogression poses operational risk.
Source: AMN 10-K Risk Factors: 'In our international nurse business, we recruit registered nurses from outside of the United States who rely on visas...Visa retrogression...has had and may in the future have a negative impact on our international nursing volumes.'

Disclosed initiatives

Recruitment & Retention Infrastructure

Company invests in technology-enabled recruitment strategies, competitive compensation packages, and national infrastructure to attract and retain healthcare professionals.

Supports workforce stability but impact on wages and working conditions not quantified.
Credentialing & Compliance

Third-party credentialing and compliance systems to ensure quality and licensure of healthcare professionals.

Ensures professional standards but does not directly address worker compensation or safety.

Governance story

AMN Healthcare Services operates with single-class common stock (no dual-class structure penalty applies). Board independence percentage is not disclosed in source documents; governance conservatively assumes below 75% threshold and applies standard penalty. Company does not disclose active lobbying expenditures or identifiable climate/consumer-protection deregulation lobbying efforts in source documents; no penalty applied. Significant regulatory and legal exposure documented: wage-and-hour litigation, employment classification disputes, antitrust investigation risks (acknowledged as growing risk as company scales), privacy/cybersecurity incident exposure, and AI regulatory uncertainty. Goodwill impairment charges ($109.5M in 2025) and long-lived asset impairments ($18.3M in 2025) indicate past valuation challenges but not active fraud/consent decrees. No evidence of shareholder litigation or SEC enforcement orders in source documents.

Criticisms on file

Wage-and-hour litigation and NLRB investigation exposure: Company subject to individual, representative and class action lawsuits for alleged wage-and-hour violations under California and Federal law; exposure to NLRB inquiries related to wage practices and employment classification.
Source: AMN 10-K Risk Factors: 'Investigations, claims and legal proceedings alleging...violations of employment, privacy and wage regulations'
Antitrust investigation risk: Company acknowledges growing antitrust exposure as market leader in healthcare staffing; environment of clinician labor shortage may invite pricing conduct inquiries.
Source: AMN 10-K Risk Factors: 'As we grow and increase our leadership position, we are at greater risk for anti-competitive conduct claims and investigations...This may lead to claims and investigations into pricing and competitive conduct in the healthcare staffing industry.'
Privacy and cybersecurity incident exposure: Company collects substantial personally identifiable information and healthcare data; acknowledges immaterial cyber incidents and expects ongoing threats.
Source: AMN 10-K Risk Factors: 'Security breaches and cybersecurity incidents could compromise our information and systems...The Company has experienced cyber threats resulting in immaterial cyber incidents and expects cyber threats to continue.'
AI regulatory uncertainty: Company uses and intends to expand AI in operations; acknowledges undefined legal/regulatory regime for AI may require significant resource commitments to comply with emerging U.S. and non-U.S. laws.
Source: AMN 10-K Risk Factors: 'As we incorporate AI and machine learning into our business there are uncertainties in the legal regulatory regime relating to AI that may require significant resources to modify and maintain our business practices...'
Goodwill and intangible asset impairments: Company recognized $109.5M goodwill impairment loss and $18.3M long-lived asset impairment loss in 2025; acknowledges risk of additional impairments in future evaluations.
Source: AMN 10-K Risk Factors & MD&A: 'During the year ended December 31, 2025, we recognized a goodwill impairment loss totaling $109.5 million and a long-lived assets impairment loss totaling $18.3 million.'

Disclosed initiatives

Enterprise Risk Management Program

Formal ERM program to identify and prioritize business risks informed by industry trends, market environment, and organizational dialogue.

Governance framework for risk identification but effectiveness not independently verified.
Compliance & Legal Accrual Management

Maintenance of accruals for legal matters, captive insurance, and self-insured retentions; periodic review by insurance brokers, attorneys, and actuarial firms.

Mitigates unexpected liability spikes but indicates substantial ongoing legal/insurance exposure.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of AMN Healthcare Services, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open AMN Healthcare Services, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)